

on September 21, 1998. The draft strategy is also available on the World Wide Web at <http://www.nrcs.usda.gov> or <http://www.epa.gov/owm/afostat.htm>.

USDA and EPA welcome your comments on the draft Unified National Strategy for AFOs. Comments are due by January 19, 1999.

Dated: November 9, 1998.

**Glenda Humiston,**

*Deputy Under Secretary, Natural Resources and the Environment, Department of Agriculture, Washington, DC.*

**J. Charles Fox,**

*Assistant Administrator for Water, Environmental Protection Agency, Washington, DC.*

[FR Doc. 98-30666 Filed 11-16-98; 8:45 am]

BILLING CODE 3410-16-P

## DEPARTMENT OF AGRICULTURE

### Agricultural Research Service

#### Notice of Intent to Grant Exclusive License

**AGENCY:** Agricultural Research Service, USDA.

**ACTION:** Notice of intent.

**SUMMARY:** Notice is hereby given that the U.S. Department of Agriculture, Agricultural Research Service, intends to grant to Agdia Incorporated of Elkhart, Indiana, an exclusive license to S.N. 08/499,803, "A Monoclonal Antibody to Vitellin of the Corn Earworm, *Helicoverpa zea*," filed July 7, 1995, U.S. Patent No. 5,656,437, issued August 12, 1997. Notice of Availability was published in the **Federal Register** on December 14, 1995.

**DATES:** Comments must be received on or before January 19, 1999.

**ADDRESSES:** Send comments to: USDA, ARS, Office of Technology Transfer, Room 401, Building 005, BARC-W, 10300 Baltimore Avenue, Beltsville MD 20705-2350.

**FOR FURTHER INFORMATION CONTACT:** W.J. Phelps of the Office of Technology Transfer at the Beltsville address given above; telephone 301-504-6532.

**SUPPLEMENTARY INFORMATION:** The Federal Government's patent rights to this invention are assigned to the United States of America, as represented by the Secretary of Agriculture. It is in the public interest to so license this invention as Agdia Incorporated has submitted a complete and sufficient application for a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within sixty (60) calendar days from the date of this published Notice, the Agricultural Research Service receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

**Richard M. Parry, Jr.,**

*Assistant Administrator.*

[FR Doc. 98-30670 Filed 11-16-98; 8:45 am]

BILLING CODE 3410-03-P

## DEPARTMENT OF AGRICULTURE

### Animal and Plant Health Inspection Service

[Docket No. 98-111-1]

#### Availability of an Environmental Assessment and Finding of No Significant Impact for Field Testing Pseudorabies Vaccine, Modified Live Virus

**AGENCY:** Animal and Plant Health Inspection Service, USDA.

**ACTION:** Notice.

**SUMMARY:** We are advising the public that the Animal and Plant Health Inspection Service has prepared an environmental assessment and finding of no significant impact concerning authorization to ship for the purpose of field testing, and then to field test, an unlicensed live viral pseudorabies vaccine for use in swine. A risk analysis, which forms the basis for the environmental assessment, has led us to conclude that field testing this veterinary vaccine will not have a significant impact on the quality of the human environment. Based on our finding of no significant impact, we have determined that an environmental impact statement need not be prepared. We intend to authorize shipment of this vaccine for field testing 14 days after the date of this notice, unless new, substantial issues bearing on the effects of this action are brought to our attention. We also intend to issue a veterinary biological product license for this vaccine, provided the field test data support the conclusions of the environmental assessment and finding of no significant impact and the product meets all other requirements for licensure.

**ADDRESSES:** Copies of the environmental assessment and finding of no significant impact may be obtained by contacting the person listed under **FOR FURTHER INFORMATION CONTACT**. Please refer to the docket number, date, and complete title

of this notice when requesting copies. Copies of the environmental assessment and finding of no significant impact (as well as the risk analysis with confidential business information removed) are available for public inspection at USDA, room 1141, South Building, 14th Street and Independence Avenue SW., Washington, DC, between 8 a.m. and 4:30 p.m., Monday through Friday, except holidays. Persons wishing to inspect those documents are requested to call ahead on (202) 690-2817 to facilitate entry into the reading room.

**FOR FURTHER INFORMATION CONTACT:** Dr. Jeanette Greenberg, Technical Writer-Editor, Center for Veterinary Biologics, Licensing and Policy Development, VS, APHIS, USDA, 4700 River Road Unit 148, Riverdale, MD 20737-1231; telephone (301) 734-5338; fax (301) 734-4314; or e-mail: [Jeanette.B.Greenberg@usda.gov](mailto:Jeanette.B.Greenberg@usda.gov).

**SUPPLEMENTARY INFORMATION:** Under the Virus-Serum-Toxin Act (21 U.S.C. 151 *et seq.*), a veterinary biological product must be shown to be pure, safe, potent, and efficacious before a veterinary biological product license may be issued. A field test is generally necessary to satisfy prelicensing requirements for veterinary biological products. Prior to conducting a field test on an unlicensed product, an applicant must obtain approval from the Animal and Plant Health Inspection Service (APHIS), as well as obtain APHIS' authorization to ship the product for field testing.

In determining whether to authorize shipment and grant approval for the field testing of the unlicensed product referenced in this notice, APHIS conducted a risk analysis to assess the potential effects of this product on the safety of animals, public health, and the environment. Based on the risk analysis, APHIS has prepared an environmental assessment (EA). APHIS has concluded that field testing the unlicensed veterinary biological product will not significantly affect the quality of the human environment. Based on this finding of no significant impact (FONSI), we have determined that there is no need to prepare an environmental impact statement.

The EA and FONSI have been prepared by APHIS concerning the field testing of the following unlicensed veterinary biological product:

*Requester:* Ambico, Inc.

*Product:* Pseudorabies Vaccine, Modified Live Virus

*Field test locations:* Iowa, Indiana, and Minnesota.

The above-mentioned vaccine is for use as an aid in the program to eradicate